PR Newswire
DUBLIN, April 10, 2024
Two oral presentations share results of real-world impact of idiopathic hypersomnia and long-term effectiveness of Epidiolex® (cannabidiol) in treatment-resistant epilepsies
Thirteen abstracts underscore Jazz's diverse neuroscience portfolio and pioneering efforts to continue advancing the treatment of serious sleep disorders, rare epilepsy syndromes and movement disorders
DUBLIN, April 10, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts from across its neuroscience portfolio and pipeline, including two oral presentations, will be featured at the 76th Annual American Academy of Neurology Meeting (AAN) being held April 13-18, 2024, in Denver.
Two encore datasets were selected for oral presentations, including results from a real-world claims analysis that demonstrated the increased risk of comorbid conditions, such as stroke or cardiovascular disease, in individuals living with idiopathic hypersomnia compared to those without the condition. Additional data being presented include a post-hoc analysis from the Epidiolex® (cannabidiol) oral solution Expanded Access Program (EAP) that explores the long-term effectiveness of Epidiolex on reduction of treatment-resistant focal-onset seizures.
"Jazz's presentations at the 2024 AAN Annual Meeting reflect our leadership in sleep and rare epilepsies, as well as our commitment to developing therapies for debilitating, and often overlooked, neurological disorders," said Rob Iannone, MD, MSCE, executive vice president and global head of research and development of Jazz Pharmaceuticals. "We remain committed to expanding our knowledge of the patient experience, including the real-world impact and effectiveness of our products, in order to achieve our purpose of transforming the lives of patients and their families."
Highlights at the 2024 AAN Annual Meeting include:
The 2024 AAN Annual Meeting abstracts are available online at https://index.mirasmart.com/AAN2024/.
A full list of Jazz-sponsored presentations follows:
Presentation Title | Presenting Author | Date / Time (MDT) / Session Title / Presentation Number |
Idiopathic Hypersomnia Data | ||
Real-World Idiopathic Hypersomnia Total Health Model (RHYTHM): Clinical Burden of Patients Diagnosed With Idiopathic Hypersomnia | J Black
| Type: Oral Session Name: S36: Sleep Neurology Highlights Code: S36.009 Session Date/Time: Wednesday, April 17, 5:06PM |
Minimal Clinically Important Difference for the Visual Analog Scale for Sleep Inertia Using Data From a Phase 3 Trial of Low-Sodium Oxybate for Idiopathic Hypersomnia | L Schneider | Type: Poster Session Name: P10: Sleep 3 Code: P10.005 Session Date/Time: Wednesday, April 17, 11:45AM – 12:45PM |
Efficacy of Low-Sodium Oxybate by Baseline Sleep Inertia in a Phase 3 Clinical Study in Participants with Idiopathic Hypersomnia | M Whalen | Type: Poster Session Name: P10: Sleep 3 Code: P10.003 Session Date/Time: Wednesday, April 17, 11:45AM – 12:45PM |
Narcolepsy Data | ||
Effectiveness and Optimization of Low-Sodium Oxybate in Participants with Narcolepsy Switching From Sodium Oxybate: Final Data From the Substitution of Equal Grams of Uninterrupted Xyrem to Xywav (SEGUE) Study | D Fuller | Type: Poster Session Name: P10: Sleep 3 Code: P10.001 Session Date/Time: Wednesday, April 17, 11:45AM – 12:45PM |
Effects of Oxybate on Sleep, Sleep Architecture, and Disrupted Nighttime Sleep | J Black | Type: Poster Session Name: P10: Sleep 3 Code: P10.006 Session Date/Time: Wednesday, April 17, 11:45AM – 12:45PM |
Epilepsy Data | ||
Long-term Effectiveness of Cannabidiol (CBD) Against Focal-Onset Seizures in Treatment-Resistant Epilepsies (TRE): Experience from the Expanded Access Program (EAP) | YD Park | Type: Oral Session Name: S29: Epilepsy Diagnostics and Therapeutic Code: S29.005 Session Date/Time: Wednesday, April 17, 1:48PM |
Real-World Treatment Patterns of Patients with Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS) in the United States (U.S.) | SV Kothare | Type: Poster Session Name: P1: Epilepsy / Clinical Neurophysiology (EEG): Pediatric Epilepsy 1 Code: P1.005 Session Date/Time: Sunday, April 14, 8:00AM – 9:00AM |
Real-world Safety and Effectiveness of Cannabidiol (CBD) in Adults with Treatment-Resistant Epilepsies (TREs): Long-term Results From the United States Expanded Access Program (EAP) | JP Szaflarski | Type: Poster Session Name: P8: Epilepsy / Clinical Neurophysiology (EEG): Anti-seizure Medications: Clinical Trials and Outcomes Code: P8.002 Session Date/Time: Tuesday, April 16, 5:30PM – 6:30PM |
Caregiver-Reported Seizure Outcomes with Real-World Use of Cannabidiol (CBD) in Tuberous Sclerosis Complex (TSC): Interim Results from the BECOME-TSC Survey | MK Koenig | Type: Poster Session Name: P8: Epilepsy / Clinical Neurophysiology (EEG): Anti-seizure Medications: Clinical Trials and Outcomes Code: P8.005 Session Date/Time: Tuesday, April 16, 5:30PM – 6:30PM |
Caregiver-Reported Nonseizure Outcomes with Real-World Use of Cannabidiol (CBD) in Tuberous Sclerosis Complex (TSC): Interim Results From the BECOME-TSC Survey | S Wilson | Type: Poster Session Name: P8: Epilepsy / Clinical Neurophysiology (EEG): Anti-seizure Medications: Clinical Trials and Outcomes Code: P8.010 Session Date/Time: Tuesday, April 16, 5:30PM – 6:30PM |
Long-Term Effectiveness of Cannabidiol (CBD) Against Focal Seizures in Tuberous Sclerosis Complex (TSC): Results From the GWPCARE6 Open-Label Extension (OLE) Trial
| JY Wu
| Type: Poster Werbung Mehr Nachrichten zur Jazz Pharmaceuticals Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1 ![]() Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News |